These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 27722984

  • 21. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
    Kerr DA, Brcic I, Diaz-Perez JA, Shih A, Wilky BA, Pretell-Mazzini J, Subhawong TK, Nielsen GP, Rosenberg AE.
    Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
    [Abstract] [Full Text] [Related]

  • 22. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 23. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.
    Chow LT.
    Virchows Arch; 2016 Jun 15; 468(6):741-55. PubMed ID: 27003154
    [Abstract] [Full Text] [Related]

  • 24. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May 15; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 25. Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.
    Kumar R, Mallya V, Mandal S, Tomar R, Khurana N, Maini L.
    J Cancer Res Ther; 2023 May 15; 19(3):768-772. PubMed ID: 37470608
    [Abstract] [Full Text] [Related]

  • 26. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T.
    Ann Oncol; 2015 Oct 15; 26(10):2149-54. PubMed ID: 26205395
    [Abstract] [Full Text] [Related]

  • 27. Histopathological Features Of Denosumab Treated Giant Cell Tumours Of Bone "A Single Institutional Experience" At A Tertiary Care Center, Karachi.
    Ali SM, Yaqoob N, Aftab Aslam K, Tauseef S, Ahmed SK, Jilani SAA, Jamal S.
    J Ayub Med Coll Abbottabad; 2022 Oct 15; 34(1):73-81. PubMed ID: 35466631
    [Abstract] [Full Text] [Related]

  • 28. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.
    Park MJ, Ganjoo KN, Ladd AL.
    J Hand Surg Am; 2015 Aug 15; 40(8):1620-4. PubMed ID: 25935517
    [Abstract] [Full Text] [Related]

  • 29. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 Aug 15; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan 15; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 32. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone.
    Suehara Y, Okubo T, Kurihara T, Hayashi T, Kohsaka S, Kazuno S, Sano K, Hasegawa N, Miura Y, Akaike K, Kim Y, Takamochi K, Takahashi F, Ueno T, Kaneko K, Saito T.
    Proteomics Clin Appl; 2019 Sep 01; 13(5):e1800147. PubMed ID: 31287244
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature.
    Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J.
    Arch Orthop Trauma Surg; 2019 Oct 01; 139(10):1339-1349. PubMed ID: 30877429
    [Abstract] [Full Text] [Related]

  • 37. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 01; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
    Al Farii H, McChesney G, Patel SS, Rhines LD, Lewis VO, Bird JE.
    Spine J; 2024 Jun 01; 24(6):1056-1064. PubMed ID: 38301904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.